| Name | Title | Contact Details |
|---|
Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers.
Alternatives Technologies Pharma Inc. is a Chicoutimi, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ankyra is developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response.
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.
MaxCyte is a US-based global company dedicated to accelerating the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines.